Benchmark analyst Michael Ward maintains Lear (NYSE:LEA) with a Buy and raises the price target from $162 to $170.
Expert Ratings for Aldeyra Therapeutics
Within the last quarter, Aldeyra Therapeutics (NASDAQ:ALDX) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat…